NGD Infection Prevention

What NGD Infection Prevention does

NGD Infection Prevention is a private clinical genomics company that provides an end-to-end whole-genome sequencing (WGS) based system for detecting bacterial transmission in hospitals. The platform combines the NGD200 automated sample preparation instrument (capable of preparing up to 48 bacterial samples in approximately 4 hours without specialized personnel, now supporting both Illumina and Oxford Nanopore sequencing platforms) with the EpiAssist bioinformatics pipeline, an internally developed, eight-plus-year-old analysis system with an interactive user interface that operates HIPAA-compliantly inside a hospital firewall. The EpiAssist module builds timelines of patients, wards, locations, procedures, and shared caregivers to help infection prevention teams identify transmission root causes, and validated machine learning models support antibiotic susceptibility prediction (peer-reviewed in the Journal of Clinical Microbiology) and ongoing cefiderocol resistance work via the NGD Cefiderocol Data Consortium. Validated machine learning models for whole genome sequence-based determination of bacterial susceptibility to antibiotics underpin the platform's claimed accuracy advantage over the in vitro standard of care.

The company was spun off from Next Gen Diagnostics effective January 1, 2025 and operates from a US headquarters in Boston, MA, a main laboratory in Kendall Square, Cambridge, MA, and a UK engineering and bioinformatics office in Cambridge, UK, with additional presence in Israel through NGD Israel, Ltd. (a subsidiary) anchored at Sheba Medical Center. Revenue is generated through enterprise multi-year, quote-based contracts with acute care hospitals and integrated delivery networks (IDNs) of all sizes, bundling NGD200 instrumentation, EpiAssist software, and recurring sequencing and bioinformatics services. Go-to-market is a direct enterprise field-sales motion targeting hospital infection prevention teams and clinical microbiology laboratories, supplemented by an event-driven presence at major conferences (ID Week, SHEA Spring, Becker's Healthcare). Named customers include Henry Ford Health, Addenbrooke's Hospital (Cambridge, UK), Vanderbilt University Medical Center, and Sheba Medical Center.

Name

NGD Infection Prevention

Legal name

NGD Infection Prevention

Website

https://ngdinfectionprevention.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

NGD Infection Prevention provides an end-to-end whole-genome sequencing system combining the NGD200 automated sample preparation instrument with the EpiAssist bioinformatics platform, enabling hospitals and IDNs to detect bacterial transmission in real time for infection prevention teams and clinical microbiology laboratories.

Ownership category

akta.pro rank

Product category

Hospital Infection Prevention Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Laboratory-Based Surveillance & Genomic Epidemiology (WGS/NGS) (HLAJABAC), Emerging Pathogen & Outbreak Response Testing Networks (HLAJAIAE), Hospital Epidemiology & Infection Prevention (HLAKAGAF), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Hospital infection prevention
• Bacterial transmission detection
• Whole genome sequencing
• Clinical microbiology diagnostics
• Antimicrobial resistance surveillance

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. WGS-Based Transmission Detection System: End-to-end sequencing and analysis service enabling hospitals to detect infection transmission in real-time. Includes NGD200 sample preparation system, bioinformatics analysis, and actionable reporting for infection prevention teams.
2. NGD200 Sample Preparation System: Sale of the NGD200 automated bacterial sample preparation instrument for hospital microbiology labs.
3. Sequencing and Bioinformatics Service: Low-cost bacterial whole genome sequencing combined with complete bioinformatics results including transmission detection reports and antibiotic resistance analysis.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

NGD Infection Prevention provides an end-to-end, on-premise whole genome sequencing-based infection transmission detection system for hospitals and integrated delivery networks. The NGD System combines the NGD200 automated bacterial sample preparation instrument with the EpiAssist bioinformatics analysis platform to deliver actionable transmission detection reports within approximately 24 hours of isolate readiness, enabling infection prevention teams to identify bacterial transmission pathways, curtail outbreaks, and reduce hospital-acquired infections.

Product overview

NGD Infection Prevention offers a unified platform combining the NGD200 automated sample preparation system with the EpiAssist bioinformatics and user interface. The NGD System is an end-to-end solution for whole genome sequencing-based bacterial infection transmission detection in hospitals. The system provides real-time visibility into bacterial transmission, enabling infection prevention teams to detect outbreaks earlier, intervene faster, and improve patient outcomes. The platform delivers actionable transmission insights within approximately 24 hours of isolate readiness using automated sample preparation, low-cost WGS, and validated bioinformatics analysis.

Differentiator

Problem solved

Functional benefit

Products and services

• NGD200 Automated Bacterial Sample Preparation System Fully automated sample preparation robotic system purpose-built for hospital microbiology labs. Prepares up to 48 bacterial samples in a single run in approximately 4 hours, delivering barcoded samples ready for sequencing. Supports both Illumina short-read and Oxford Nanopore long-read sequencing platforms and enables routine sequencing without specialized personnel.
• EpiAssist Bioinformatic Analysis Platform Automated and validated bioinformatics system developed over 8 years that rapidly determines whether sequenced samples are linked to one another or to prior isolates. Includes an interactive epidemiologic user interface that builds timelines of patients, wards, locations, procedures, and shared caregivers. Operates in a HIPAA-compliant manner entirely within the hospital firewall and scales to compare samples against thousands sequenced in the previous year.
• NGD System (End-to-End WGS Transmission Detection Platform) End-to-end whole genome sequencing-based infection transmission detection system combining the NGD200 automated sample preparation with EpiAssist bioinformatic analysis. Delivers actionable transmission insights within approximately 24 hours of isolate readiness, providing real-time visibility into bacterial transmission for hospital infection prevention teams. Designed for hospitals and IDNs of all sizes; cost-effective, easy to use, and requires minimal training.
• Low-Cost Bacterial Whole Genome Sequencing and Bioinformatics Service Usage-based sequencing and bioinformatics service providing low-cost bacterial whole genome sequencing combined with complete bioinformatics results including transmission detection reports and antibiotic resistance analysis. Operates in conjunction with the NGD200 and EpiAssist as the ongoing service component of the NGD System deployment.

Quantifiable outcome

• ROI greater than 20:1 when applied at operational surveillance scale
• +2 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Dr. Lee Harrison and Dr. Alex SundermanncoreStrategic or Co-development Partner · 17 June 2025Dr. Lee Harrison (Professor of Epidemiology at Pitt, Director of UPMC Center for Genomic Epidemiology) chairs NGD's Infection Prevention Advisory Board. Dr. Alex Sundermann (Assistant Professor of Epidemiology at Pitt, expert in genomic outbreak detection) serves as NGD's Lead Consultant for Infection Prevention Services.
• Sheba Medical CentercoreStrategic or Co-development Partner · 9 March 2025Comprehensive partnership with the largest medical center in the Middle East (ranked among top 10 globally by Newsweek for 8 consecutive years). Includes deployment of NGD200 system for real-time transmission detection, collaboration on studying drug-resistant bacteria, and sequencing/analyzing Sheba's unique collection of highly resistant bacterial strains for infection control and AMR research.
• University of PittsburghcoreStrategic or Co-development Partner · 10 February 2025University of Pittsburgh joined the NGD Consortium as part of efforts to develop sequence-based diagnostic models to predict susceptibility to cefiderocol antibiotic. Dr. Lee Harrison (Professor of Epidemiology, Director of UPMC Center for Genomic Epidemiology) chairs NGD's Infection Prevention Advisory Board.
• New York State Department of Health Wadsworth CenterminorStrategic or Co-development Partner · 19 November 2024Wadsworth Center joined the NGD Cefiderocol Data Consortium for the sequencing-based determination of cefiderocol resistance. Supports development of sequence-based diagnostic tool to predict resistance to cefiderocol.
• Vanderbilt University Medical CenterminorStrategic or Co-development Partner · 20 May 2024Collaborative study demonstrating that WGS detected substantial transmission of infection in a neonatal intensive care unit not detected by conventional infection control procedures, even in a highly resourced medical center.
• Standard BioToolscoreTechnology or Integration · 26 February 2024Long-term exclusive agreement for Standard BioTools to manufacture the NGD-100, a customized version of its microfluidics-based Biomark X9 System optimized for automated pathogen WGS library preparation. Enables complete automation of low-cost pathogen sequencing workflow.

Scale indicators5 records

Recent moves13 records

Expansion highlights6 records

Emerging players

• Accelerate Diagnostics: Accelerate Diagnostics provides rapid identification and antibiotic susceptibility testing for bloodstream infections, addressing a subset of the infection prevention and antimicrobial stewardship workflow that NGD's WGS platform targets with a different technological approach.
• Specific Diagnostics: Specific Diagnostics is an emerging player developing rapid, phenotypic antibiotic susceptibility testing for bloodstream infections; competes for the same hospital infection prevention and antimicrobial stewardship budget that NGD's genomic surveillance platform targets via a complementary technology approach.
• T2 Biosystems: T2 Biosystems offers direct-from-sample molecular diagnostics for bloodstream and biothreat infections in hospital settings, competing for infection prevention budget and clinical microbiology lab workflows that NGD targets with WGS-based surveillance.

Direct peers

• Day Zero Diagnostics: Day Zero Diagnostics offers whole-genome sequencing-based bacterial identification and infection control analytics, directly comparable to NGD's automated WGS transmission detection workflow for hospital microbiology and outbreak response.

Others

• Illumina: Illumina is a key upstream sequencing platform provider whose short-read sequencers underpin NGD's workflow; relevant as both an enabling technology partner and a potential long-term competitive risk if Illumina expands into clinical infectious disease surveillance.
• Oxford Nanopore Technologies: Oxford Nanopore's long-read sequencing platform was added to NGD200's supported platforms, making it a core enabling technology for NGD's expanding workflow; relevant as both a partner and adjacent technology provider in clinical microbiology.

Broad incumbents

• Becton, Dickinson and Company (BD): BD is a major incumbent in hospital-acquired infection prevention and clinical microbiology (BD MAX, BD Phoenix, BD Synapsys), competing for the same infection prevention budget and serving similar hospital customers as NGD across a much broader product portfolio.
• bioMérieux: bioMérieux is a global leader in clinical microbiology and industrial diagnostics with a broad portfolio (VITEK, BioBall, BioFire FilmArray, EPISEQ SARS-CoV-2) that overlaps NGD's hospital microbiology and infection control target use cases, though it does not focus specifically on WGS-based transmission surveillance.
• Cepheid (Danaher): Cepheid's GeneXpert molecular diagnostic systems are widely deployed in hospital microbiology labs for infectious disease testing; their installed base and rapid-test economics represent both a competitor and a complementary workflow to NGD's sequencing-based surveillance approach.
• BioFire Diagnostics (bioMérieux subsidiary): BioFire FilmArray syndromic panels are widely used in hospital settings for rapid infectious disease diagnosis and infection control workflows, broadly comparable to NGD's clinical microbiology and infection prevention positioning though focused on rapid PCR panels rather than WGS surveillance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NGD Infection Prevention